3-Deazaneplanocin A (DZNep) is an indirect inhibitor of EZH2 currently in the pre-clinical phase of drug development and has been shown to promote apoptosis in various primary tumor cells and cancer cell lines [15–20]. The gene discussed is EZH2; the disease is cancer.